Cambridge, Mass.– KalVista Pharmaceuticals has signed a licensing agreement with Pendopharm, granting the Canadian firm exclusive rights to seek regulatory approval and commercialize sebetralstat in Canada. The drug, currently under investigation, could become the first oral on-demand treatment available in the country for hereditary angioedema (HAE), a rare genetic disorder marked by severe swelling attacks.
Sebetralstat is being developed as an alternative to current injectable therapies for HAE, which require refrigeration and may be less convenient for patients during unexpected attacks. KalVista, which is advancing the drug globally, said the partnership with Pendopharm supports its strategy to expand market access beyond the U.S. and Europe.
Pendopharm, a division of Pharmascience Inc., is known for commercializing therapies across multiple disease areas in Canada and will lead both regulatory submissions and eventual market launch.
While financial terms of the deal were not disclosed, KalVista CEO Ben Palleiko said the collaboration reflects confidence in sebetralstat’s potential and Pendopharm’s ability to deliver it to Canadian patients.
The agreement comes as KalVista continues clinical development of the drug and prepares for potential approvals in other markets.
